Results 151 to 160 of about 410,064 (307)

NOCICEPTIN/ORPHANIN FQ RECEPTOR LIGANDS: PHARMACOLOGICAL STUDIES

open access: yes, 2009
The neuropeptide nociceptin/orphanin FQ (N/OFQ) selectively binds and activates the N/OFQ peptide (NOP) receptor. At cellular level N/OFQ inhibits cAMP accumulation and Ca2+ conductance and stimulates K+ currents.
Fischetti, Carmela   +1 more
core  

Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer. [PDF]

open access: yesBMC Cancer, 2017
Lin C   +6 more
europepmc   +1 more source

ABL kinase‐dependent phosphorylation of SH proteins promotes their direct interaction with CRK family SH2 domains

open access: yesFEBS Letters, EarlyView.
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are signaling adaptors driving cell adhesion, motility, differentiation, and proliferation. SH2‐domain containing (SH) proteins are enriched in YXXP motifs which when phosphorylated create preferred binding sites for CRK family SH2 domains.
Phoebe M. Cousens   +8 more
wiley   +1 more source

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar

open access: yesVascular Health and Risk Management, 2014
Jung Rae Cho, Fabiana Rollini, Francesco Franchi, Elisabetta Ferrante, Dominick J Angiolillo University of Florida College of Medicine – Jacksonville, Jacksonville, FL, USA Abstract: Platelet activation with subsequent aggregation is a complex ...
Cho JR   +4 more
doaj  

PAR-1 thrombin receptor antagonist

open access: yesJapanese Journal of Thrombosis and Hemostasis, 2012
openaire   +2 more sources

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

open access: yesMolecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce   +11 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

open access: yesMolecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Ligand-induced selective signalling at the gonadotrophin releasing hormone receptor

open access: yes, 2008
Includes abstract.Includes bibliographical references (p. 179-202).The pituitary gonadotrophin releasing hormone (GnRH) receptor regulates reproduction by activation of Gq/11 proteins.
Coetsee, Marla Catherine
core  

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

open access: yesMolecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy